February 4, 2020 See PDF: Coalition Letter Urging Support for HR 2339 2.4.20 (1) U.S. House of Representatives Washington, DC 20515 Dear Representative: We are writing to express our strong support for H.R. 2339, the Reversing the Youth Tobacco Epidemic Act of 2019. This legislation will address the current youth e-cigarette epidemic that is undermining […]
Read More »On Health Policy
Written Statement to the First Selectman’s Capital Improvement Program’s Public Hearing Regarding Dangers of Artificial Turf
January 9, 2020. Officials in communities all over the country have been misled by artificial turf salespeople. They were erroneously told that these products are safe. But on the contrary, there is clear scientific evidence that these materials are potentially harmful. The only question is how harmful and how much exposure is likely to be harmful? We should not be willing to take such a risk. Our children deserve better.
Read More »NCHR’s Comments on NIH Draft Policy on Data Sharing
January 3, 2020. Our Center has supported data sharing, and particularly for data funded by federal agencies or submitted to federal agencies as part of application materials to the FDA and other federal agencies.
Read More »NCHR’s Comments on FDA’s Best Practices in Drug and Biological Product Postmarket Safety Surveillance
January 6, 2020. The draft document describes how FDA staff evaluates postmarket safety surveillance but lacks some essential information about FAERS, post-marketing studies, the Sentinel Initiative, and safety signal resolution.
Read More »NCHR Comments FDA’s Draft Guidance on Clinical Decision Support Software
December 23, 2019.We appreciate FDA clarifying plans for regulating Clinical Decision Support (CDS) software; however, we have concerns regarding the draft guidance.
Read More »